Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI), which is changing its corporate name to Axe Compute Inc. with an expected ticker transition to AGPU, generates news at the intersection of AI‑driven oncology, capital markets activity, and digital asset‑enabled AI infrastructure. Company announcements emphasize its use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for cancer patients, as well as its newer digital asset treasury strategy focused on ATH, the native utility token of the Aethir network.
News updates frequently cover financial results and corporate updates, including quarterly earnings releases, shareholder letters, and discussions of operating performance. These communications often describe progress in validating proprietary technologies, such as the PEDAL AI platform and the ChemoFx live‑cell tumor profiling assay, along with efforts to expand the availability of ChemoFx in the United States and prepare for a de novo launch in Europe.
Investors following POAI can also expect transaction and financing news, such as private placements involving cash and digital assets, reverse stock split announcements, at‑the‑market offering updates, and standby equity purchase agreements. Recent disclosures describe substantial private investment in support of the company’s digital asset treasury strategy, as well as Nasdaq compliance updates related to stockholders’ equity and bid price requirements.
Another recurring theme in the news flow is strategic partnerships and governance developments. Examples include the strategic collaboration with Every Cure on drug repurposing, collaborations related to 3D liver toxicity models, and appointments of new board members and senior leaders to support the digital asset treasury and AI initiatives. Updates on the evolution of the company’s business model, including the creation of a Strategic Compute Reserve through ATH holdings on the Aethir ecosystem, are also highlighted.
For readers and investors, the POAI news page provides a consolidated view of these developments, allowing closer tracking of the company’s oncology‑focused AI activities, its digital asset strategy, and key regulatory and listing milestones.
Predictive Oncology Inc. (NASDAQ: POAI) has announced successful study results demonstrating the long-term stability and viability of over 150,000 cryopreserved patient tumor samples in its proprietary biobank. The study showed 100% concordance in drug response results between original fresh patient sample testing and long-term cryogenically stored tumor material, some preserved for up to 16 years.
This validation is important for predicting patient outcomes, guiding personalized therapies, target validation, and in silico modeling of drug-tumor responses. The company's biobank, containing 150,000+ tumor specimens, 200,000+ pathology slides, and 20 years of actionable data, positions Predictive Oncology as a key player in AI-driven drug discovery. The global biospecimen market, valued at $4.4 billion in 2023, is expected to reach $11.7 billion by 2031, growing at a CAGR of over 13%.
Predictive Oncology (Nasdaq: POAI) reported Q2 2024 financial results, with a net loss of $3.2 million on total revenue of $0.3 million. Key highlights include:
1. Entry into the biomarker discovery market, estimated at $51.5 billion in 2024, following successful development of multi-omic machine learning models for ovarian cancer.
2. Implementation of a cost savings initiative expected to reduce cash used in operating activities by 20% annually.
3. Cash and cash equivalents of $5.3 million as of June 30, 2024.
4. Revenue decrease to $278,722 in Q2 2024 from $490,110 in Q2 2023.
5. Gross profit margin declined to 45% from 67% year-over-year.
6. Reduced expenses across general and administrative, operations, and sales and marketing categories.
Predictive Oncology Inc. (NASDAQ: POAI) has expanded applications for its AI-driven drug discovery platform to address patient heterogeneity and improve drug development success rates. The company's approach integrates artificial intelligence, machine learning, and a biobank of cryopreserved patient-derived tumor samples to introduce patient heterogeneity earlier in the drug discovery process. This strategy aims to increase the Probability of Technical Success (PTS) for drug candidates, potentially reducing failures in late-stage clinical trials.
The platform's capabilities include comprehensive patient sample response analysis, biomarker discovery, clinical trial optimization, and target validation. By leveraging these tools, Predictive Oncology seeks to help pharmaceutical companies make more informed decisions about drug development, potentially accelerating timelines and improving resource allocation in oncology R&D.
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging AI and machine learning for oncology drug discovery, has announced it will report its Q2 2024 financial results on Wednesday, August 14, 2024, before market open. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET on the same day.
Investors can access the call via toll-free (877-407-3982) or international (201-493-6780) numbers, using Conference ID 13748154. A live webcast will also be available on the company's investor relations website.
Predictive Oncology Inc. (NASDAQ: POAI) has announced a definitive agreement for the exercise of existing warrants to purchase 958,117 shares of common stock at a reduced price of $1.32 per share, down from the original $14.00. This exercise is expected to generate gross proceeds of approximately $1.26 million for the company. In return, Predictive Oncology will issue new unregistered Series A and B warrants, each for up to 958,117 shares, with an exercise price of $1.07 per share.
The transaction, set to close around July 26, 2024, will provide working capital for the company. This funding, combined with $3.58 million raised in May 2024 through an at-the-market facility, will be used for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for this transaction.
Predictive Oncology Inc. (NASDAQ: POAI) has announced its expansion into the biomarker discovery market, leveraging its AI/ML-driven drug discovery platform. This move follows successful results from a retrospective ovarian cancer study with UPMC Magee-Womens Hospital, presented at the 2024 ASCO Annual Meeting. The study demonstrated the company's ability to develop multi-omic machine learning models that more accurately predict patient survival outcomes compared to clinical data alone.
The company aims to discover novel biomarkers for predicting patient outcomes and drug responses in oncology, with potential applications beyond ovarian cancer. This initiative is expected to create additional revenue streams and enhance the value of Predictive Oncology's diverse patient samples and data. The total biomarker discovery market is estimated to be $51.5 billion in 2024.
Predictive Oncology (NASDAQ: POAI) has developed a novel stem cell expression system for producing functional G-Protein Coupled Receptors (GPCRs), important for cancer research.
GPCRs play a significant role in cancer tumorigenesis and represent over 30% of the therapeutic drug market, valued at nearly $3.5 billion in 2022, with an annual growth rate of 5% through 2030.
The company has filed intellectual property protection for its proprietary GPCR expression platform, which is expected to create significant partnering opportunities in drug discovery and development.
This platform will be combined with their High-Throughput Self-Interaction Chromatography (HSC™) technology to enhance the solubility and stability of GPCRs, addressing existing challenges in the field.
The new technology is anticipated to launch later this year or early 2025, opening up a multi-billion-dollar market opportunity.
Predictive Oncology (NASDAQ: POAI) has launched a unique 3D cell culture model to enhance cancer drug discovery and future drug development. These organ-specific in vitro models better mimic human tissue compared to traditional 2D assays, allowing for more accurate clinical outcome predictions and optimized candidate selection for clinical trials.
The global 3D cell culture market is projected to grow from $1.4 billion in 2022 to nearly $5.3 billion by 2032, driven by applications in pharmaceuticals, regenerative medicine, cancer research, and toxicology. The technology aims to reduce time-to-market and costs, decrease animal testing, and improve clinical trial efficiency.
The company's efforts in developing 3D organoids and spheroids, enhanced by AI and machine learning, have shown promising results, with recent presentations at the Society for Laboratory Automation and Screening (SLAS) in Boston.
Predictive Oncology (NASDAQ: POAI) announced that CEO Raymond Vennare will present at the BIO International Convention 2024 in San Diego from June 3-6. Vennare will discuss the company's AI-driven drug discovery capabilities, which leverage a proprietary biobank of over 150,000 tumor samples. The firm's assets include advanced AI, a CLIA-certified wet lab, and pathology slides, enabling robust predictions through real-world experimentation. The presentation, titled 'Novel AI Driven Insights to Guide Early Drug Discovery,' is scheduled for June 3rd at 3:45 PM PDT. This event is a significant platform for biopharmaceutical stakeholders globally.
Predictive Oncology (NASDAQ: POAI) has announced positive outcomes from a retrospective study in partnership with UPMC Magee-Womens Hospital.
The study, which will be presented at the 2024 ASCO Annual Meeting, demonstrated AI-driven multi-omic machine learning models that predict survival outcomes in ovarian cancer patients more accurately than clinical data alone.
Key findings include the use of patient data and sequencing to train 160 models, with seven models showing high prediction accuracy at the two-year threshold and 13 at the five-year threshold.
This advancement offers potential improvements in clinical management and personalized treatment plans.
Presentation details: June 3rd, 9:00am-12:00pm CDT, by Dr. Brian Christopher Orr.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
